No Prescription |
 |
 | ||
|
TARIVID Floxin |
|
| ||
No Prescription » Prescription Drugs 15 » TARIVID Floxin Ofloxacin is an antibiotic used to treat certain infections caused by bacteria such as pneumonia; bronchitis; venereal disease (VD); and prostate skin and urinary tract infections. Antibiotics will not work for colds flu or other viral infections.It is usually taken with or without food every 12 hours (twice a day) for 3-10 days. Some infections may take up to 6 weeks or longer. To treat VD a single dose is taken. Buy TARIVID Floxin and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About TARIVID Floxin: Product Type: Prescription Drugs 15 TARIVID ( Floxin Generic Ofloxacin ) TARIVID (Floxin Generic Ofloxacin) Floxin Generic Ofloxacin 200mg Tabs Floxin Generic Ofloxacin TARIVID
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
